Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Colorcon
AstraZeneca
Baxter

Last Updated: June 28, 2022

Details for Patent: 8,835,501


✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,835,501 protect, and when does it expire?

Patent 8,835,501 protects BELEODAQ and is included in one NDA.

This patent has forty-one patent family members in twenty-six countries.

Summary for Patent: 8,835,501
Title:Pharmaceutical formulations of HDAC inhibitors
Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s): Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee: TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:11/913,191
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,835,501
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Device;

Drugs Protected by US Patent 8,835,501

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acrotech BELEODAQ belinostat POWDER;INTRAVENOUS 206256-001 Jul 3, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,835,501

PCT Information
PCT FiledMay 11, 2006PCT Application Number:PCT/GB2006/001737
PCT Publication Date:November 16, 2006PCT Publication Number: WO2006/120456

International Family Members for US Patent 8,835,501

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 542527 See Plans and Pricing
Australia 2006245495 See Plans and Pricing
Brazil PI0610128 See Plans and Pricing
Canada 2606598 See Plans and Pricing
China 101189003 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
McKinsey
Merck
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.